11 results about "Pregnancy outcomes" patented technology

The present application relates to the technical field of medical data fusion processing, and discloses a method and system for predicting adverse pregnancy outcomes of preeclampsia by fusing placental microenvironment image features and serum biomarkers, wherein the method comprises: obtaining digital whole field image of placental tissue section and serum biomarker detection data at the same period; constructing a multi-modal sample data set; extracting multi-scale structure features of placental microenvironment; constructing serum biomarker discriminant features; dynamically fusing placental image features and serum marker features; constructing a prediction model for adverse pregnancy outcomes of preeclampsia and outputting a prediction probability. Compared with the prior art which only relies on single image information or single serum biomarker for risk assessment, it is difficult to realize stable prediction of the coordinated changes of placental microenvironment abnormalities and biochemical abnormalities. Due to the multi-scale image structure analysis, the model generalization ability for predicting adverse pregnancy outcomes of preeclampsia is improved.

The invention discloses a blood mtDNACN-based system, method and application for evaluating an adverse pregnancy outcome risk, and the system comprises a data obtaining module which is used for obtaining blood mtDNACN detection data; the risk assessment module is used for storing a pre-constructed causal risk assessment model; and the result output module is used for outputting a risk assessment result. The model is constructed based on a Mendel randomization method, SNP significantly related to blood mtDNACN is used as a tool variable, and the lactic acid metabolism level hybrid effect is innovatively corrected, so that the lactic acid metabolism level hybrid effect of a subject is corrected without depending on lactic acid parameters of the subject. The causal association between the blood mtDNACN and the specific adverse pregnancy outcome (including gestational hypertension, preeclampsia, premature rupture of fetal membranes and the like) is accurately determined. According to the scheme provided by the invention, more reliable and anti-hybrid individualized risk assessment can be realized, and a new tool is provided for health management in the gestation period.

This invention provides a method and system for integrated data correlation analysis based on clinical features and molecular indicators, belonging to the field of medical data processing and intelligent prediction technology. The method includes: preprocessing collected clinical feature data and molecular indicator data to obtain a standardized structured dataset; extracting key clinical feature subsets and key molecular indicator subsets from the standardized structured dataset, and fusing them to generate a unified multidimensional fusion feature vector; dynamically calibrating at least three clinical phenotypic benchmarks in the unified multidimensional fusion feature vector using a clinical feature data spectrum, whereby the clinical phenotypic benchmarks are defined based on age feature spectrum nodes, infertility course trajectory critical scaling, and endometrial thickness quantification cutoff values. This invention can effectively complete the integrated correlation analysis of clinical features and molecular indicators and predict pregnancy outcomes, meeting the needs of precision clinical diagnosis and treatment.

This invention discloses a method and system for predicting pregnancy outcomes in ovulation induction cycles for PCOS patients, belonging to the field of medical artificial intelligence technology. The method includes: acquiring static and dynamic features of PCOS patients; extracting three time-series derived features from the dynamic features: dominant follicle growth rate, multiple follicle synchronous development index, and follicle size uniformity; inputting the static features into a static channel composed of a fully connected neural network, and inputting the time-series derived features into a dynamic channel composed of a gated recurrent unit network; concatenating the outputs of the two channels in a fusion layer and outputting the pregnancy probability through a classification head. This invention, through a dual-channel architecture that fuses baseline clinical parameters and follicle growth dynamic features, achieves a prediction AUC of 0.79, providing effective support for ovulation induction treatment decisions for PCOS patients.

This invention relates to the field of medical data analysis, and more particularly to a method for assessing the risk of pregnancy outcomes in pregnant women based on multifactor feature analysis. The method includes: acquiring individual measured time-series datasets and baseline reference data for physiological expectations; obtaining a gestational age-specific pathological surge penalty factor by weighting the ratio of angiogenic factors to anti-angiogenic factors; obtaining a cross-system pathological cascade time coupling factor by temporally tracing and coupling abnormal deviations in vascular system indicators and blood system indicators; obtaining a fused feature vector by correcting and fusing the initial linear regression slope features; and obtaining the pregnancy outcome risk assessment result by performing machine learning prediction on the fused feature vector. This method solves the problem that existing prediction methods based on linear regression slope extraction and feature splicing cannot effectively identify gestational age-specific early high-risk signals and cross-system short-term pathological cascade signals.

The invention relates to a microfluidic device, method, and use for the continuous, label-free isolation of motile, morphologically normal spermatozoa from semen samples This invention offers a gentle, reliable, and efficient platform for sperm selection, serving as an alternative to centrifugation-based techniques in ART laboratories. By maintaining the structural and genetic integrity of sperm, it improves fertilization success, embryo quality, and pregnancy outcomes. The platform also reduces variability between technicians and limits exposure to reactive oxygen species (ROS), ensuring consistent clinical performance. Beyond its application in fertility treatments, the system can be used as a diagnostic tool to assess sperm motility disorders, susceptibility to oxidative stress, and DNA fragmentation dynamics under different environmental conditions or drug exposures.

Diagnostic microarray devices, kits, and methods of treating or reducing the occurrence of various conditions or diseases are disclosed, wherein the conditions or diseases include (but are not limited to) periodontal disease, Alzheimer's disease, cardiovascular disease, arthritis, and adverse pregnancy outcomes. The devices, kits, and methods utilize an analysis of single nucleotide polymorphisms (SNPs) from various interleukins.

The invention belongs to the technical field of animal breeding. More specifically, the invention relates to a method for predicting ewe embryo transplantation pregnancy results. The research finds that luteinizing hormone, cortisol and prostaglandin E2 in the estrus period of the ewe have significant correlation with the pregnancy result after the ewe embryo transplantation in a specific concentration range for the first time, and ROC curve analysis proves that the three can be used as biomarkers for predicting the pregnancy result after the ewe embryo transplantation. On the basis, the invention provides a method for predicting the pregnancy result of ewe embryo transplantation, and the pregnancy result is predicted according to the concentration of the reproductive hormone by detecting the concentration of the reproductive hormone in the peripheral blood of the receptor ewe in the estrus period. According to the method, pregnancy potential evaluation can be realized before transplantation, and the prediction timeliness is remarkably improved. In addition, breeding managers can screen high-pregnancy-potential individuals accordingly, and breeding efficiency is improved. The hormone abuse condition in embryo transplantation is reduced, the culture cost is reduced, and the method has good application prospects and value.

This invention relates to the field of biotechnology and provides a gene-modified mouse model for tracking migratory organisms, its construction method, and its applications. The invention achieves precise labeling of endogenous migratory organisms by fusing the key structural protein TSPAN4 of the migratory organism with the fluorescent tag RFP and the modification tag Avi-tag, and site-specifically integrating it into the H11 site of mice, thus obtaining a TSPAN4-overexpressing transgenic mouse model. By introducing an LSL structure, the fusion gene is kept in a state of expression shutdown, achieving temporal and spatial specific activation only after mating with tissue-specific Cre tool mice. Multidimensional validation has shown that this model can accurately track migratory organisms in placental trophoblast cells, providing a standardized tool for assessing disease progression under physiological and pathological conditions through differences in migratory organism trajectory, inclusion packaging, and assembly, and can be directly applied to mechanistic studies and drug screening for diseases such as adverse pregnancy outcomes.

The invention relates to a microfluidic device, method, and use for the continuous, label-free isolation of motile, morphologically normal spermatozoa from semen samples This invention offers a gentle, reliable, and efficient platform for sperm selection, serving as an alternative to centrifugation-based techniques in ART laboratories. By maintaining the structural and genetic integrity of sperm, it improves fertilization success, embryo quality, and pregnancy outcomes. The platform also reduces variability between technicians and limits exposure to reactive oxygen species (ROS), ensuring consistent clinical performance. Beyond its application in fertility treatments, the system can be used as a diagnostic tool to assess sperm motility disorders, susceptibility to oxidative stress, and DNA fragmentation dynamics under different environmental conditions or drug exposures.

This invention relates to the use of baicalin in the preparation of drugs for treating and / or alleviating preeclampsia. The drugs are used to inhibit ferroptosis in placental trophoblasts and / or placental tissue, manifested by increasing the expression level of at least one of GPX4, SLC7A11, and FTH1, increasing GSH content and / or GPX activity, and decreasing Fe... 2+ It can reduce MDA, lipid ROS and / or mitochondrial ROS levels, and improve preeclampsia-related hypertension, proteinuria, placental oxidative stress and adverse pregnancy outcomes. This application can be used to prepare preeclampsia treatment and / or alleviation drugs with baicalin monomer as the active ingredient.